MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - May 10, 2013) - MorphoSys AG
(FSE: MOR; Prime Standard Segment; TecDAX) announced today that a
first scientific publication on the Company's novel, proprietary
platform Ylanthia was published in the current issue of "mAbs". The
titled "A fully synthetic human Fab antibody library based on fixed
framework pairings with favorable biophysical properties" describes
first time the detailed design, generation and testing of the Ylanthia
Ylanthia became commercially available for existing and new partners in
is currently used in two commercial agreements.
"Ylanthia sets new standards for therapeutic antibody generation. Its
innovative design translates into unprecedented structural diversity
expected to result in antibodies against previously inaccessible
molecules and covering a unique epitope space. Furthermore, our
introduced an entirely new concept to improve biophysical characteristics
are relevant for antibody selection, manufacturing and administration,
leading to better drugs," commented Dr. Marlies Sproll, Chief Scientific
of MorphoSys AG.
To confirm the functionality and quality of the Ylanthia antibody library,
selections against several antigens were performed. Subsequent
characterization revealed broad diversity and significantly improved
properties including a very low aggregation tendency, increased
stability and favorable solubility of Ylanthia antibodies.
Ylanthia comprises more than 100 billion distinct, fully human antibodies,
makes it the industry's largest known antibody Fab library. It uses 36
naturally-occurring heavy and light chain framework combinations,
translates into very broad structural diversity. Ylanthia's antibody
were pre-selected for favorable expression levels, stability and
behavior. A shift towards higher stability and stress tolerance will
shelf life and serum stability of resulting antibody products, making them
cost-effective to produce. A higher solubility in turn opens up the
more convenient ways of administration, to the benefit of patients. When
antibodies from the Ylanthia library are optimized using MorphoSys's
Slonomics technology. Slonomics enables optimization of Ylanthia antibodies
unprecedented speed and flexibility.
The full paper is available on
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE